These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

75 related items for PubMed ID: 23159841

  • 1. Clinical application of the different cross-reactivities of anti-insulin antibodies to insulin lispro to evaluate endogenous insulin secretion.
    Yoshida R, Ohkubo K, Akehi Y, Harada S, Shinohara K, Kawashima H, Ono J, Matsunaga A.
    Clin Chim Acta; 2013 Jan 16; 415():250-4. PubMed ID: 23159841
    [Abstract] [Full Text] [Related]

  • 2. A single-center, randomized, double-blind, three-way crossover study examining postchallenge glucose responses to human insulin 70/30 and insulin lispro fixed mixtures 75/25 and 50/50 in patients with type 2 diabetes mellitus.
    Schwartz S, Zagar AJ, Althouse SK, Pinaire JA, Holcombe JH.
    Clin Ther; 2006 Oct 16; 28(10):1649-57. PubMed ID: 17157120
    [Abstract] [Full Text] [Related]

  • 3. A study comparing insulin lispro mix 25 with glargine plus lispro therapy in patients with Type 2 diabetes who have inadequate glycaemic control on oral anti-hyperglycaemic medication: results of the PARADIGM study.
    Bowering K, Reed VA, Felicio JS, Landry J, Ji L, Oliveira J.
    Diabet Med; 2012 Sep 16; 29(9):e263-72. PubMed ID: 22672081
    [Abstract] [Full Text] [Related]

  • 4. The addition of acarbose to insulin lispro reduces acute glycaemic responses in patients with type-2 diabetes.
    Hermanns N, Burkert A, Haak T.
    Exp Clin Endocrinol Diabetes; 2004 Jun 16; 112(6):310-4. PubMed ID: 15216448
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics of insulin lispro in type 2 diabetes during closed-loop insulin delivery.
    Ruan Y, Thabit H, Kumareswaran K, Hovorka R.
    Comput Methods Programs Biomed; 2014 Nov 16; 117(2):298-307. PubMed ID: 25092225
    [Abstract] [Full Text] [Related]

  • 6. U-100, pH-Neutral formulation of VIAject(®) : faster onset of action than insulin lispro in patients with type 1 diabetes.
    Heinemann L, Nosek L, Flacke F, Albus K, Krasner A, Pichotta P, Heise T, Steiner S.
    Diabetes Obes Metab; 2012 Mar 16; 14(3):222-7. PubMed ID: 21981286
    [Abstract] [Full Text] [Related]

  • 7. Reduction in intrasubject variability in the pharmacokinetic response to insulin after subcutaneous co-administration with recombinant human hyaluronidase in healthy volunteers.
    Morrow L, Muchmore DB, Ludington EA, Vaughn DE, Hompesch M.
    Diabetes Technol Ther; 2011 Oct 16; 13(10):1039-45. PubMed ID: 21714645
    [Abstract] [Full Text] [Related]

  • 8. Comparison of Subcutaneous Regular Insulin and Lispro Insulin in Diabetics Receiving Continuous Nutrition: A Numerical Study.
    Stull MC, Strilka RJ, Clemens MS, Armen SB.
    J Diabetes Sci Technol; 2015 Jun 30; 10(1):137-44. PubMed ID: 26134836
    [Abstract] [Full Text] [Related]

  • 9. Comparison of 70/30 biphasic insulin with glargine/lispro regimen in non-critically ill diabetic patients on continuous enteral nutrition therapy.
    Hsia E, Seggelke SA, Gibbs J, Rasouli N, Draznin B.
    Nutr Clin Pract; 2011 Dec 30; 26(6):714-7. PubMed ID: 22205560
    [Abstract] [Full Text] [Related]

  • 10. Performance evaluation and cross-reactivity from insulin analogs with the ARCHITECT insulin assay.
    Moriyama M, Hayashi N, Ohyabu C, Mukai M, Kawano S, Kumagai S.
    Clin Chem; 2006 Jul 30; 52(7):1423-6. PubMed ID: 16690737
    [Abstract] [Full Text] [Related]

  • 11. Preprandial combination of lispro and NPH insulin improves overall blood glucose control in type 1 diabetic patients: a multicenter randomized crossover trial.
    Annuzzi G, Del Prato S, Arcari R, Bellomo Damato A, Benzi L, Bruttomesso D, Calderini MC, Coscelli C, Fedele D, Galluzzo A, Giordano M, Giorgino R, Lapolla A, Orsini P, Pagano G, Santoro D, Riccardi G.
    Nutr Metab Cardiovasc Dis; 2001 Jun 30; 11(3):168-75. PubMed ID: 11590992
    [Abstract] [Full Text] [Related]

  • 12. Effect of long-term exposure to insulin lispro on the induction of antibody response in patients with type 1 or type 2 diabetes.
    Fineberg SE, Huang J, Brunelle R, Gulliya KS, Anderson JH.
    Diabetes Care; 2003 Jan 30; 26(1):89-96. PubMed ID: 12502663
    [Abstract] [Full Text] [Related]

  • 13. Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects.
    Becker RH, Frick AD, Burger F, Potgieter JH, Scholtz H.
    Exp Clin Endocrinol Diabetes; 2005 Sep 30; 113(8):435-43. PubMed ID: 16151977
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of subcutaneous insulin lispro versus continuous intravenous regular insulin for the treatment of patients with diabetic ketoacidosis.
    Umpierrez GE, Latif K, Stoever J, Cuervo R, Park L, Freire AX, E Kitabchi A.
    Am J Med; 2004 Sep 01; 117(5):291-6. PubMed ID: 15336577
    [Abstract] [Full Text] [Related]

  • 15. Effects of regular insulin or insulin LISPRO on glucose metabolism after an oral glucose load in patients with type 2 diabetes mellitus.
    Paquot N, Roulin D, Schneiter P, Ruiz J, Lefebvre P, Pahud P, Tappy L.
    Diabetes Metab; 1998 Dec 01; 24(6):523-8. PubMed ID: 9932219
    [Abstract] [Full Text] [Related]

  • 16. Treatment of type 1 diabetes with insulin lispro during Ramadan.
    Kadiri A, Al-Nakhi A, El-Ghazali S, Jabbar A, Al Arouj M, Akram J, Wyatt J, Assem A, Ristic S.
    Diabetes Metab; 2001 Sep 01; 27(4 Pt 1):482-6. PubMed ID: 11547222
    [Abstract] [Full Text] [Related]

  • 17. A comparison of preprandial insulin glulisine versus insulin lispro in people with Type 2 diabetes over a 12-h period.
    Luzio S, Peter R, Dunseath GJ, Mustafa L, Owens DR.
    Diabetes Res Clin Pract; 2008 Feb 01; 79(2):269-75. PubMed ID: 18164094
    [Abstract] [Full Text] [Related]

  • 18. Cessation of insulin infusion at night-time during CSII-therapy: comparison of regular human insulin and insulin lispro.
    Reichel A, Rietzsch H, Köhler HJ, Pfützner A, Gudat U, Schulze J.
    Exp Clin Endocrinol Diabetes; 1998 Feb 01; 106(3):168-72. PubMed ID: 9710355
    [Abstract] [Full Text] [Related]

  • 19. Use of insulin immunoassays in clinical studies involving rapid-acting insulin analogues: Bi-insulin IRMA preliminary assessment.
    Agin A, Jeandidier N, Gasser F, Grucker D, Sapin R.
    Clin Chem Lab Med; 2006 Feb 01; 44(11):1379-82. PubMed ID: 17087654
    [Abstract] [Full Text] [Related]

  • 20. Lispro analog for treatment of generalized allergy to human insulin.
    Kumar D.
    Diabetes Care; 1997 Sep 01; 20(9):1357-9. PubMed ID: 9283778
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.